Associate Scientist I, Discovery Chemistry (Bioconjugation) jobs in United States
cer-icon
Apply on Employer Site
company-logo

Arrowhead Pharmaceuticals · 3 weeks ago

Associate Scientist I, Discovery Chemistry (Bioconjugation)

Arrowhead Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing innovative drugs for genetic diseases. They are seeking an Associate Scientist to join their Discovery Chemistry team in San Diego, primarily focusing on oligonucleotide bioconjugation, peptide synthesis, and analytical chemistry to support the development of siRNA-based therapeutics.

BiotechnologyHealth CareNanotechnologyPharmaceutical
check
Comp. & Benefits
badNo H1Bnote

Responsibilities

Maintain a well-documented laboratory notebook
Track progress against project timelines, generate regular status updates, and communicate progress and issues to management
Perform tasks across projects
Manage time effectively to meet deadlines
Adhere to safe laboratory practices
Prioritize and perform synthesis, purification, and analysis of conjugates based on project deliverable timelines

Qualification

Oligonucleotide bioconjugationPeptide synthesisAnalytical chemistryHPLCOrganic chemistryBiochemistryLaboratory practicesLearning new techniquesTime management

Required

B.S. or M.S. Chemistry or Biochemistry degree with excellent understanding of organic and analytical chemistry
0-3 years of experience working in a chemistry laboratory
Experience with a wide range of analytical techniques, especially HPLC
Ability to quickly learn new procedures and techniques

Preferred

Experience working with large-molecule synthetic targets, particularly oligonucleotides, in an academic or industry setting
Experience with solid-phase peptide synthesis (automated and/or manual)
Prior experience in a pharmaceutical or biotechnology environment

Benefits

Competitive salaries
Excellent benefit package

Company

Arrowhead Pharmaceuticals

twittertwittertwitter
company-logo
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.

Funding

Current Stage
Public Company
Total Funding
$2.45B
Key Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2026-01-07Post Ipo Equity· $200M
2026-01-07Post Ipo Debt· $625M
2024-11-26Post Ipo Equity· $325M

Leadership Team

leader-logo
Christopher Anzalone
President and Chief Executive Officer
Company data provided by crunchbase